Rheinmetall shares slump 16% after second 2026 outlook cut in Q3 results

Rheinmetall cut its 2026 sales outlook to around €13.20 billion from €13.70 billion–€14.20 billion, lowered its operating-margin target to 18.5% from around 19%, and reduced expected cash conversion to just over 0% from more than 40%, citing delayed orders and deliveries. Shares fell as much as 16.3%. Third-quarter operating profit beat consensus at €553 million versus €531.4 million, but sales, adjusted EPS and operating free cash flow missed expectations; nine-month operating free cash flow was -€1.70 billion versus -€798 million a year earlier.

Analysis

The key change is not weaker end-demand but lower confidence in converting defense backlog into recognized revenue and cash on schedule. That shifts the near-term valuation debate from order growth to execution quality: delayed acceptance defers revenue and advance payments, while inventory accumulation and the cash-conversion reset make the balance-sheet cost of slippage more visible. The operating-profit beat is lower quality evidence than it appears given the sales miss, weaker adjusted EPS, cash outflow, and reported EBIT support from special items.

Near term (days), the sharp repricing may already discount much of the 2026 estimate reset; avoid chasing the gap before price discovery. Over 1–3 months, watch for customer acceptance, shipment timing and inventory conversion, especially in ammunition and Vehicle Systems. If management preserves 2027 delivery timing, this is chiefly a timing/cash-flow setback; further slippage would raise the risk that backlog quality and cash conversion are structurally weaker than investors assume. Over 6–18 months, European rearmament demand may remain supportive, but execution credibility can drive relative performance: peers such as BAE Systems, Leonardo, Saab and Thales may be favored if they demonstrate more dependable delivery and cash conversion. Air Defence strength is an offset, not yet evidence that it can compensate for the broader shortfall.

Contrarian point: the share-price shock and Q3 operating-profit beat can distract from the more consequential signal—cash conversion has deteriorated sharply and net debt has replaced net liquidity. Conversely, the delay itself does not establish lost demand; confirmed 2027 catch-up could prompt a recovery.

Key Decisions for Investors

• Do not add to RHM at the open solely on the earnings beat; wait for post-gap stabilization and the next evidence on acceptance and cash conversion.
• Consider a small relative-value short RHM versus a diversified European defense peer basket (e.g., BAE Systems, Leonardo, Saab and Thales) only if RHM fails to recover after the initial repricing. The thesis is execution/cash-flow underperformance, not a collapse in sector demand; avoid a large outright short after a 16% decline.
• Treat confirmed Arminius and ammunition delivery/acceptance dates, inventory reduction, and operating free cash flow as the 1–3 month catalysts. A further delay, or continued inventory growth, would strengthen the underweight; verified catch-up into 2027 and improving cash generation would falsify it.
• Before increasing conviction, verify the detailed 2027 revenue phasing and whether advance payments are contractually deferred or at risk. Without that detail, do not capitalize the delayed sales as certain recovery.